Western blot analysis showed that treatment of pancreatic cancer cells for 48 h with increasing concentrations of pristimerin resulted in a dose-dependent decrease in the levels of the anti-apoptotic proteins Bcl-XL and Bcl-2 (Fig. 5). Here, BCL2L1 is linked to familial pancreatic carcinoma.